drugset
drugset / Trial / NCT04542252

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

NCT04542252 ↗

Phase 1 Completed 13 enrolled SymBio Pharmaceuticals
RandomizedCrossoverOpen-labelBasic science

Summary

To evaluate the effect of coadministered cyclosporine on the pharmacokinetics of brincidofovir following simultaneous administration of SyB V-1901 with cyclosporine, or coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion in healthy adult subjects

Timeline

Start
2020-11-09
Primary completion
2020-12-22
Completion
2021-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Brincidofovir Other / unclassified 10 mg Intravenous
Subject Cyclosporine Peptide 200 mg —

Indications

No indication recorded.